Unknown

Dataset Information

0

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry.


ABSTRACT: INTRODUCTION:Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germany. METHODS AND RESULTS:The APAF registry is a prospective non-interventional study enrolling 5015 patients with non-valvular atrial fibrillation. Of these, 1349 (26.9%) patients were initially treated with apixaban and followed up at 3 and 12 months. The dose of apixaban used was 1 × 2.5 mg in 1.6%, 2 × 2.5 mg in 30.4%, and 2 × 5 mg daily in 68.0% of patients, respectively. Inappropriate underdosing of apixaban was observed in 22.3%, mostly in elderly patients with higher HAS-BLED Score and a history of bleeding. Persistence to apixaban after 1 year was 88.6%, while the dose was changed in 3.7% of patients. Switching to other NOACs or VKAs occurred in 5.1%. After 12 months, all-cause mortality was 5.0%, non-fatal stroke occurred in 0.4%, non-fatal myocardial infarction in 0.6%, ISTH major bleeding in 0.8%, moderate or minor bleeding in 4.3% of patients, respectively. CONCLUSIONS:In this prospective experience in unselected patients with atrial fibrillation, persistence to apixaban was high, and efficacy and safety were comparable to the results in clinical trials, supporting its use in clinical practice.

SUBMITTER: Zeymer U 

PROVIDER: S-EPMC7584711 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry.

Zeymer Uwe U   Lober Christiane C   Wolf Andreas A   Richard Frank F   Schäfer Heinrich H   Taggeselle Jens J   Kabitz Hans-Joachim HJ   Prondzinsky Roland R   Süselbeck Tim T  

Cardiology and therapy 20200708 2


<h4>Introduction</h4>Apixaban has been shown to be superior to warfarin in patients with non-valvular atrial fibrillation in the randomized ARISTOTLE trial and its use is recommended in current guidelines. There are only scarce data about its use, efficacy, and safety in unselected patients in Germany.<h4>Methods and results</h4>The APAF registry is a prospective non-interventional study enrolling 5015 patients with non-valvular atrial fibrillation. Of these, 1349 (26.9%) patients were initially  ...[more]

Similar Datasets

| S-EPMC5634552 | biostudies-literature
| S-EPMC10878325 | biostudies-literature
| S-EPMC10798445 | biostudies-literature
| S-EPMC10889502 | biostudies-literature
2018-04-12 | GSE113013 | GEO
| S-EPMC7383111 | biostudies-literature
| S-EPMC9061668 | biostudies-literature
| S-EPMC4928891 | biostudies-literature
| S-EPMC6735819 | biostudies-literature
| S-EPMC6709911 | biostudies-literature